In The News

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

  • Becker's Hospital Review named Dana-Farber/Brigham and Women's Cancer Center to the 2014 edition of "100 Hospitals and Health Systems With Great Oncology Programs."

Tags: Honors

  • The U.S. News and World Report Best Hospitals Guide has ranked Dana-Farber/Brigham and Women's Cancer Center the highest in New England for cancer care for the 14th straight year and fourth overall in the country.

Tags: Featured, Honors

  • An editorial written by physicians at Dana-Farber supports a study showing there is no compelling evidence to justify using testosterone suppression therapy on men with early-stage prostate cancer.

Tags: ProstateCancer

  • Dr. Ian E. Krop led a study showing that the anti-body drug ado-trastuzumab emtansine significantly prolonged progression-free survival in patients with progressive HER2-positive advanced breast cancer.

Tags: BreastCancer

  • Dr. Eric P. Winer co-chaired an expert panel that developed a clinical practice guideline on disease management for patients with advanced HER2-positive breast cancer and brain metastases.

Tags: BreastCancer

  • Dr. Matthew Meyerson led a genomic study of lung cancer which has provided information that could help scientists devise new treatments.

Tags: Genomics

  • Dr. Paul L. Nguyen led a study showing prostate cancer patients with health insurance are less likely to have metastatic disease or die from the cancer than those without health insurance.

Tags: ProstateCancer

  • Dr. Robert Haddad commented on JPMorgan Chase CEO Jamie Dimon being diagnosed with throat cancer.

Tags: HeadNeckCancers

  • Dr. Joyce Liu commented on the Oncologic Drugs Advisory Committee vote to delay approval of the PARP inhibitor olaparib.

Tags: OvarianCancer

  • Johnson & Johnson Innovation Center will fund a $10 million partnership with Dana-Farber and Janssen Biotech to work on lung cancer immunotherapy drugs.

Tags: Immunotherapy

Showing 11-20 of 421 items